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Recent studies have shown that genes involved in oxidative phosphorylation 
(OXPHOS) exhibit reduced expression in skeletal muscle of diabetic and 
prediabetic humans. Moreover, these changes may be mediated by the 
transcriptional co-activator peroxisome proliferator-activated receptorg co-
activator-1a  (PGC-1a) 1,2.  By combining PGC-1a -induced genome-wide 
transcriptional profiles with a computational strategy to detect cis-regulatory 
motifs, we identified estrogen receptor-related receptora  (Erra) and GA-binding 
protein a (Gabpa) as key transcription factors regulating the OXPHOS pathway.  
Interestingly, the genes encoding these two transcription factors are themselves 
PGC-1a -inducible and contain variants of both motifs near their promoters.  
Cellular assays confirmed that Erra and Gabpa partner with PGC-1a in muscle to 
form a double-positive feedback loop that drives the expression of many 
OXPHOS genes.  By using a synthetic inhibitor of Erra, we demonstrated its key 
role in PGC-1a-mediated effects on gene regulation and cellular respiration. 
These results illustrate the dissection of gene regulatory networks in a complex 
mammalian system, elucidate the mechanism of PGC-1a action in the OXPHOS 
pathway, and suggest that Erra  agonists may ameliorate insulin -resistance in 
individuals with type 2 diabetes mellitus. 
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Peroxisome proliferator-activated receptor-g co-activator 1-a and 1-b (PGC-1-a and -b) 
responsive genes involved in oxidative phosphorylation show reduced expression in 
muscle from patients with type 2 diabetes mellitus.  These changes are also observed in 
healthy first degree relatives of diabetics as well as in individuals with impaired glucose 
tolerance, suggesting that these defects are causally linked to the development of 
insulin resistance.  Combined with recent morphologic and functional studies 3-5, these 
reports indicate that a PGC-1-mediated dysregulation in mitochondrial biogenesis is 
important in the development of human diabetes. 
     PGC-1-a and -b are transcriptional co-activators involved in the regulation of several 
key metabolic processes, including mitochondrial biogenesis, adaptive thermogenesis, 
skeletal muscle fiber-type switching, and gluconeogenesis 6-12.  PGC-1a is capable of 
co-activating nearly all known nuclear receptors as well as many other transcription 
factors 13.  A pressing question now is to identify the transcription factors that specify the 
changes observed in muscle: these transcription factors may be sites of genetic 
variation or misregulation and may represent important therapeutic targets. 
     Systematic identification of transcription factors involved in biological processes in 
mammals remains a largely unsolved problem 14.  One promising approach relates 
genome-wide expression profiles to promoter sequences to discover influential cis-
motifs 15-18.  Such strategies have yielded impressive results in simple organisms such 
as yeast, but it has been challenging to extend these algorithms to mammalian 
genomes, where intergenic regions are large, annotation of gene structure is imperfect, 
and DNA sequence can be highly repetitive .  Most of these methods seek motifs by 
comparison to a fixed background model of nucleotide composition (which fails to 
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represent the fluctuations seen in large genomes) or by comparison between two sets 
of genes (which is likely to capture only very sharp differences).  Further, many of these 
methods assume that the expression data are normally distributed, which may not 
always be true. 
    To overcome some of these obstacles, we devised a simple, nonparametric strategy 
for identifying motifs associated with differential expression (motifADE) (Fig. 1a).  The 
algorithm involves three steps: (i) ranking genes based on differential expression 
between two conditions; (ii) given a candidate motif M, identifying the subset SM of 
genes whose promoter regions contains the motif M; and (iii) testing via a 
nonparametric statistic (see Methods) if the genes in SM tend to appear toward the top 
(or bottom) of the ranked list (indicating association) or are randomly distributed on the 
list.  motifADE may be applied to a specific candidate motif of interest or to the list of all 
possible motifs of a given size (in which case the significance level should be adjusted 
to reflect multiple hypothesis testing).  By using a nonparametric scoring procedure, we 
do not make assumptions about the distribution of the expression data.  Furthermore, 
by considering the entire rank ordered list, the promoters of lower rank implicitly provide 
a background of DNA composition for comparison, and there is no need to demarcate 
or cluster a group of genes as being “responsive .”  The method is quite flexible, and can 
test any set of motifs using a traditional promoter database or even a database of 
promoters that have been masked based on evolutionary conservation (see Methods). 
     To identify motifs related to PGC-1a action, we infected mouse C2C12 muscle cells 
with an adenovirus expressing PGC-1a and obtained gene expression profiles for 
12,488 genes at 0, 1, 2  , and 3 days following infection. We found 649 genes that were 
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induced at least 1.5-fold at day 3.  As expected, these were enriched for genes involved 
in carbohydrate metabolism and the mitochondrion 6,7,11,12,19 (Fig. 1c).  Somewhat 
surprisingly, many genes involved with protein synthesis (GO terms: protein 
biosynthesis, mitochondrial ribosome and ribosome) are also induced. 
     We then applied motifADE to study the 5034 genes for which there is reliable 
information about the location of the transcriptional start site (TSS) in the mouse 
genome (see Methods).  For each gene, the target region was defined to be a 2 Kb 
region centered on the TSS.  We then tested all possible n-mers ranging in size from n= 
6 to n=9 nucleotides (a total of 348,160 motifs) for association with differential 
expression on each of the three days of the timecourse.  
     A total of 20 motifs achieved high statistical significance (p<0.001, corrected for 
multiple hypothesis testing) and these were almost exclusively related to two distinct 
motifs (see Table 1 as well as the longer list in Supplemental Table S1).  The first motif, 
5’-TGACCTTG-3’ was significant on days 1, 2, and 3 (adjusted P=2.1x10-6, 2.9x10-9, 
and 7.7x10-7, respectively). It corresponds to the published binding site for the orphan 
nuclear receptor Erra 20, which is known to be capable of being co-activated by PGC-1-
a and -b 21-23.  The Erra gene is known to be involved in metabolic processes, based on 
studies showing that knockout mice have reduced body weight and peripheral fat tissue, 
as well as altered expression of genes involved in metabolic pathways 24.  The second 
motif is 5’-CTTCCG-3’ (adjusted p=8.9x10-9), which is the top scoring motif on day 3.  It 
corresponds to the published binding site for Gabpa 25, which complexes with Gabpb 26 
to form the heterodimer nuclear respiratory factor-2 (NRF-2) 27, a factor known to 
regulate the expression of some OXPHOS genes 28.  Interestingly, the reverse 
  - 7 - 
complements of these motifs did not score well, suggesting a preference for the 
orientation of these motifs relative to the TSS, and some occurrences of the motifs 
occurred downstream of the TSS.  While each of these motifs is individually associated 
with PGC-1a, our analyses suggest that a gene having both motifs typically ranks 
higher on the list of differentially expressed genes (Supplemental Fig. S1), suggesting 
that the two motifs might have an additive or synergistic effect. 
     Next, we repeated the motifADE analysis using a “masked” promoter database (see 
results in Supplemental Table S2).  We still considered the 2000 bp centered on the 
TSS, but masked these promoters so that we only considered those nucleotides aligned 
and conserved between mouse and human (see Methods).  Still, the top ranking motifs 
on days 1 and 3 were related to Erra (day 1, P=6.5x10-7; day 3 P=4x10-7) and to Gabpa 
(day 3 P=5.2x10-5), providing additional support for these motifs . 
     The Erra and Gabpa motifs are particularly enriched in the OXPHOS-CR genes, 
which have been shown to be reduced in human diabetes 1,2.  Whereas the top scoring 
Erra motif (5’-TGACCTTG-3’ or its reverse complement) only occurs in 12% of the 5034 
promoters of the database, in 29% of the PGC-responsive genes (i.e., those genes 
induced at least 1.5 fold on day 3), and in 27% of the mitochondrial genes, they are 
found in 52% of the OXPHOS-CR genes (significance of enrichment, P=1x10-4).  About 
one-half of these sites are perfectly conserved in the syntenic region in human (data not 
shown).  The top scoring Gabpa binding sites (5’-CTTCCG-3’ or its reverse 
complement) are much more common (62% of all promoters of the database and in 
79% of the PGC-responsive genes), but they, too, show significant enrichment in the 
OXPHOS-CR genes (89%, P=0.02). 
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     The results suggest that Erra and Gabpa may be key transcriptional factors 
mediating PGC-1a action in muscle.  In this connection, it is notable that based on the 
microarray data, both Erra and Gabpa are themselves induced ~2-fold (P<0.01) on day 
1 following expression PGC-1a.  The induction of these factors has been observed in 
previous studies 7,21. Moreover, careful analysis of the Erra and Gabpa genes suggest 
that each contain potential binding sites for both transcription factors within the vicinity 
of their promoters. The Erra gene has the Erra motif as well as a conserved variant of 
the Gabpa binding site 25 upstream of the TSS, while the Gabpa gene has an Erra site 
upstream of the TSS and a conserved variant of the Gabpa binding site in its first intron 
(see Fig. 2a and Methods).  These results raise the possibility that Erra and Gabpa may 
regulate their own and each other’s expression.  
     Taken together, the systematic analysis of the transcriptional program driven by 
PGC-1a in skeletal muscle suggests a model in which increases in PGC-1a protein 
levels (induced, for example, by exercise 29,30) results in increased transcriptional 
activity of Gabpa and Erra on their own promoters, leading to a stable increase in the 
expression of these two factors via a double positive-feedback loop (Fig. 2).  These two 
factors, perhaps in combination with PGC-1a, are then crucial in the induction of 
downstream target genes, many of which have binding sites for these motifs (Fig. 2).  
Such a circuit may serve as a regulatory switch, analogous to a feed-forward loop that 
plays a key role in the early stages of endomesodermal development in sea urchin 31. 
     We experimentally tested this model of gene regulation.  To determine whether Erra 
and Gabpa are indeed key transcriptional partners of PGC-1a, we tested whether the 
Erra and Gabpa proteins are co-activated by PGC-1a on the Erra and Gabpa 
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promoters.  We cloned appropriate portions of the promoters (the upstream region of 
Erra containing both sites, the upstream region of Gabpa containing the Erra site and 
the first intron of Gabpa containing the Gabpa site) into expression vectors and tested 
their ability to drive expression of a reporter gene, in the presence and absence of PGC-
1a. The results confirm the predicted co-activation between PGC-1a and the two 
transcription factors in muscle cells.  Moreover, the results for the Erra promoter 
fragment containing both sites show that the transcription factors act additively or even 
synergistically. 
     We next sought to explore the functional role of Erra in executing the PGC-1a-
mediated response, by using a recently developed, selective Erra inverse agonist, 
called XCT790, referred to below as the inhibitor. This compound does not significantly 
inhibit or activate other nuclear receptors at doses near its IC50 (583 nM) for Erra, 
although higher concentrations (above 3.3 mM) have been found to weakly activate 
PPARg  (R.A. Heyman, personal communication).  
     The inhibitor was first used to p robe the role of Erra ?in activation of the Erra and the 
Gabpa, by repeating the experiments above in the presence or absence of the inhibitor 
at a dose slightly above its IC50.  The inhibitor markedly reduced activation of the Erra 
promoter by Erra and PGC-1a, but had no effect on Gabpa/b-driven reporter gene 
expression (Fig. 4a).  The effect of the Erra inhibitor resembles the effect of site-
directed mutagenesis of the Erra binding site on the Erra promoter (Fig. 4b). 
     The role of Erra was investigated in the regulation of endogenous PGC-1a target 
genes.  PGC-1a was expressed in C2C12 myotubes, treated with inhibitor or vehicle, 
  - 10 - 
and measured the expression level of specific genes at day 1 by using RT-PCR.  We 
studied five genes that contain variants of the Erra motif, including two of the OXPHOS-
CR genes, Gabpa, and Erra, as well as medium chain acyl-CoA dehydrogenase 
(MCAD), a published target of Erra 22,32.  The expression of all of these genes is 
induced by PGC-1a, and this induction is diminished by the inhibitor (Fig. 4c).  To test 
the specificity of the response, we also evaluated two genes that are induced by PGC-
1a but yet lack obvious Erra binding sites.  These two genes, pyruvate dehydrogenase 
b and the inner mitochondrial membrane protein Immt, were not affected by the inhibitor 
(Fig. 4c). Together, these results suggest that a subset of PGC-1a genes are regulated 
by Erra and that these correspond to the target genes containing an Erra motif. The fact 
that the inhibition of these genes by the ERRa inverse agonist was not complete 
suggests that other factors might also be involved in this regulation. To ensure that the 
effects of the Erra inhibitor were not due to activation of PPARg, control experiments 
were performed using the synthetic PPARg agonist rosiglitazone and confirmed that it 
had no effect on the expression of these genes (Supplemental Fig. S2). 
     The role of Erra in the PGC-1a-mediated physiologic response was characterized 
using functional assays of mitochondrial respiration.  The Erra inhibitor potently 
diminishes PGC-1a induction of total cellular respiration and also significantly reduces 
PGC-1a triggered increases in uncoupled respiration (Fig. 5).  The data suggest that 
inhibition of Erra elicits certain aspects of a ‘diabetic phenotype’ in cultured muscle 
cells. 
     We extended the analysis to cells derived from liver, where PGC-1a has been shown 
  - 11 - 
to induce genes of the fasting response, including those involved in gluconeogenesis 
and b-oxidation of fatty acids 8,33,34.  These responses are generally elevated in poorly 
controlled diabetics.  As expected, MCAD and two key genes related to 
gluconeogenesis (glucose-6-phosphatase and phosphoenol-pyruvate carboxykinase) 
were all induced by PGC-1a. However, the Erra antagonist repressed PGC-1a-
induction of MCAD but not the gluconeogenic genes (Fig. 4d). 
Finally, we investigated the relationship of nuclear respiratory factor-1 (NRF-1) to 
ERRa function in muscle cells. NRF-1 has been suggested to be a key transcription 
factor involved in mitochondrial biogenesis 35 and is induced and co-activated by PGC-
1a in this process 7. On the other hand, transgenic overexpression of NRF-1 in muscle 
is not sufficient to induce mitochondrial biogenesis 36. Using the synthetic Erra inverse 
agonist, we found that induction of NRF-1 by PGC-1a is actually downstream of the 
initial Erra-mediated events (Supplemental Fig. S3).  Interestingly, motifADE analysis of 
the NRF-1 consensus motif (5’-GCGCAC/TGCGC-3’ or reverse complement) yields a 
score which falls far short of significance in the search over all possible motifs (in which 
P-values must be corrected for multiple hypothesis testing) but which is significant if 
considered as a test of single hypothesis (nominal P=0.001 on day 3). Overall, these 
results suggest that NRF-1 is an important but relatively late mediator of the 
mitochondrial transcriptional program induced by PGC-1a. 
The results above have computational, biological and medical implications. First, the 
motifADE algorithm provides a simple, nonparametric approach for discovering cis- 
elements by incorporating gene expression.  The method makes very few assumptions 
about the statistical properties of DNA composition or about the distribution of RNA 
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expression.  The method is flexible, and as we have shown, can easily incorporate 
“masked” or “phylogenetically footprinted” promoters from cross-species comparisons.  
With additional cross -species comparisons , it should be possible to further reduce the 
search space37-39.  Fortunately, in the current study, we were confident in the identity of 
the transcription factors binding the motifs discovered – in general this may not be the 
case, and generic, experimental strategies will be needed to systematically determine 
the occupancy of newly identified motifs.  The strategy clearly has some limitations – 
e.g., a motif may be missed if it lies outside the target promoter region, or if a functional 
binding site is too degenerate for our motif search strategy. 
Second, the analyses above indicate that the effects of PGC-1a on OXPHOS 
genes in muscle are largely mediated through Erra and Gabpa.  Recent studies have 
shown that PGC-1b can also co-activate Erra 23, and initial application of motifADE to 
cells expressing PGC-1b  suggests that these same factors are important in regulating 
this program also (data not shown).  Together, the data imply a model of gene 
regulation in which PGC-1a (and likely PGC-1b) initially induces the expression of Erra 
and Gabpa, via a double positive feedback mechanism (Fig. 2).  These transcription 
factors are then expressed at higher levels and are themselves co-activated by PGC-1 
to induce downstream genes such as NRF-1 and members of OXPHOS.  Certainly, 
other transcription factors and regulators, not identified in the current study, are involved 
in the mitochondrial biogenesis program.  Whereas previous studies have shown that 
PGC-1 interacts with and/or induces 15-20 transcription factors in various physiological 
settings (including Erra and Gabpa 7,21-23,40), the present study points to Erra and 
Gabpa as being especially important early in the timecourse in muscle and provides a 
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model of how these factors interact in executing the transcriptional program. 
     Third, the results suggest a potential approach to the treatment of type 2 diabetes. 
Recent studies in diabetic and pre-diabetic humans have demonstrated that there is a 
consistent decrease in the expression of genes of oxidative phosphorylation that are 
responsive to PGC-1a and PGC-1b  and that treatments that induce PGC-1a (such as 
exercise) lead to increased expression of OXPHOS genes and improved insulin 
sensitivity 1,2,4,5.  On its face, this might argue for developing therapeutic approaches 
that raise the transcriptional activity of PGC-1. However, PGC-1 activates many 
different pathways in many tissues and such approaches may suffer from lack of 
specificity. For example, global transgenic overexpression of PGC-1b in mice results in 
resistance to obesity induced by a high-fat diet or by a genetic abnormality, though the 
contribution of PGC-1b  expression in muscle has not been explored 23.  On the other 
hand, a global knockout of Erra also causes a leaner phenotype and resistance to high-
fat diet-induced obesity 24. Combined with the current results, this suggests that Erra 
has different functions in energy homeostasis in different tissues. The identification of 
the critical roles of Erra ?and Gabpa in mediating the transcriptional program altered in 
human diabetic muscle may offer a more specific target.  Erra plays a key role in 
muscle cells but does not appear to affect genes involved in gluconeogenesis in liver 
cells. This implies that synthetic Erra agonists, particularly those that promote docking 
of PGC-1a on Erra, may serve to ameliorate insulin resistance in human diabetic 
muscle without exacerbating hyperglycemia in the liver.  Because Erra is an orphan 
nuclear receptor, it may be an attractive drug target.   
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Methods 
Cell culture and adenoviral infection.  Mouse myoblasts (C2C12 cells) were cultured 
and differentiated into myotubes as previously described 7.  After 3 days of 
differentiation, they were transduced with an adenovirus expressing either green 
fluorescence protein or PGC-1a.  All experiments were performed in duplicate and flow 
cytometry performed to ensure nearly 100% and equivalent infection titers. 
 
mRNA isolation, target preparation, and hybridization.  Cells were harvested prior to 
(day 0) as well as 1, 2, and 3 days following viral transduction (all performed in 
duplicate, yielding 14 samples).  RNA was isolated from the cultured cells using the 
Trizol method.  cRNA targets were prepared as previously described 1 and hybridized 
onto the Affymetrix MG-U74Av2 chip.  Hence, the timecourse consists of a total of 14 
microarray experiments . 
 
Data scaling.  Data were scaled with a mean scaling procedure using the median scan 
as a reference.  The data files were then converted into the .res format for further 
analysis.  Complete timecourse data can be downloaded at http://www-
genome.wi.mit.edu/mpg/PGC_motifs/. 
 
Data Clustering, Visualization, and Annotation Enrichment.  Data were clustered 
and visualized using the dChip software package 41.  Normalized gene expression 
levels were used for data visualization.  Mitochondrial genes were defined from a recent 
report that combined proteomics and genomics to systematically identify mouse 
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mitochondrial proteins 42.  The GoSurfer tool was used to determine which annotations 
were enriched groups of genes, using a P-value of 0.01 19. 
 
Identifying Genes Responsive to PGC-1a .  For a given day, simple t-tests were 
performed to identify whether a given gene shows difference in expression between 
PGC-1a and GFP infection.  We required a 1.5-fold increase in expression and a 
nominal P-value of 0.05 as arbitrary thresholds for identifying differentially expressed 
genes.   
 
Promoter Databases.  We used the mm3 build of the mouse genome 
(http://genome.ucsc.edu) and the associated RefSeq annotation tables to construct a 
database of mouse promoters corresponding to the probe-sets on the Affymetrix MG-
U74Av2 chip.  The MG-U74Av2 chip contains a total of 12,488 probe-sets.  The mm3 
RefSeq includes annotations for 13,406 reference sequences.  Of the 12,488 probe-
sets on the MG-U74Av2 chip, 5034 map 1:1 to a RefSeq that maps uniquely in the 
mouse genome.  Our ‘mouse promoter database’ consists of the 1000 bases upstream 
and downstream (2000 BP total) surrounding the annotated transcription start site of 
these 5034 genes.   
     We also performed analyses on a ‘masked promoter database’, consisting of the 
regions within these 2000 BP that are aligned and conserved between mouse and 
human.  We used the mouse/human BLASTZ alignments (mouse mm4 vs. human 
hg16) 43 that we downloaded from the UCSC genome browser 
(http://genome.ucsc.edu/goldenPath/mm4/vsHg16/axtNet/).  We only considered the 
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4249 promoters for which the mouse:human BLASTZ alignment contained at least 100 
BP.  Finally, we masked the aligned promoters to retain mouse sequence exhibiting at 
least 70% sequence identity to human within windows of size 10.  The median promoter 
length in the masked database is ~ 1200 BP, compared to a fixed length of 2000 BP in 
the mouse promoter database. 
 
Motif discovery.  To discover motifs associated with PGC-1a responsiveness, we 
developed a program called motifADE, which a variant of the Gene Set Enrichment 
Analysis procedure recently described 1.  Comparisons are made for each day between 
the PGC-1a treated versus GFP control group.  All genes (corresponding to genes in 
the promoter database) on a given day are rank ordered on the basis of difference in 
expression, based on the signal to noise ratio (SNR) from the microarray experiment.  In 
general, the genes can be ranked by any difference metric.  Each gene is then 
annotated for the presence or absence of a motif in the promoter.  We used string 
matching to search for n-mer (where n = 6, 7, 8 or 9) or for selected motifs of interest 
defined by a regular expression. 
     To determine whether the differential expression for those genes with a given motif 
differ from those genes lacking the motif, we used the Mann-Whitney rank sum statistic.  
Because the masked promoter database consists of promoters of unequal length, a 
motif could potentially be associated with a gene simply because of promoter length.  
We corrected the Mann-Whitney statistic by explicitly taking the promoter length into 
consideration.  The null hypothesis of our correction is that a given motif occurs in a 
promoter with a probability that depends linearly on the promoter length.  This 
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distribution will be uniform for promoters sharing the same length, thereby reducing to 
the null hypothesis used in the traditional Mann-Whitney statistic. 
     To estimate the significance of a motif that occurred in C promoters with a rank sum 
of S, we compute a Z-score = (S-m)/s, where the mean m and standard deviation s is 
determined from the new null hypothesis.   Monte Carlo simulations are used to 
estimate s and m of the rank sum in the null hypothesis by randomly drawing samples of 
C promoters according to the given probability distribution.  For each C, 1000 samples 
were drawn and m and s of the rank sum estimated from the sample mean and the 
sample deviation. 
     The P-values for the association between motifs and expression have been 
subjected to a Bonferroni correction for the 4n n-mers tested, i.e, the P-values in Table 1 
represent global or adjusted P-values.  We also applied motifADE to the expression 
data, testing individual, published motifs.  The P-values reported for the association of 
these motifs are nominal P-values, since these represent single hypotheses.  Finally, 
we note that these P-values were computed under a null model of random distribution.   
     motifADE has been implemented in C and is available upon request (V.K.M.) 
 
Cotransfection assays.  The Erra and the Gabpa promoters and the Gabpa intron 1 
were amplified from genomic mouse DNA by PCR and subsequently cloned into the 
pGL3 reporter gene vectors (Promega). Transfections and reporter gene assays were 
performed as described 44. Site-directed mutagenesis was done using overlapping 
primers. Simultaneously with the transfection, cells were treated with vehicle (0.1% 
DMSO) or 1 mM of the inhibitor, XCT790, for 48 hours.  Motifs for Erra and Gabpa were 
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found at the following positions: Erra site at -585 CCGCAGTGACCTTGAGTTTTG -565 
and Gabpa site at -41 GGAGGAAGCGGAGTAGGAAGCA -20 in the Erra promoter, 
Erra? site at -614 GCGCCGTGACCTTGGGCTGCC -594 in the Gabpa promoter and 
Gabpa sites at +3 GAGTTGCGGACG +14 and +51 TGGTTCCGGGGC +62  in intron 1 
of the Gabpa gene. These motifs were either directly identified by motifADE or, in the 
case of the Gabpa binding site in the Erra promoter, found by looking for other Gabpa 
motifs that have been described 26. 
 
Semiquantitative real-time PCR. Primers for target genes were designed using the 
PrimerExpress software (ABI Biosystems). Relative gene expression was calculated 
with the DDCt method using SYBRgreen on a iCycler (Biorad). 
 
Respiration assays.  After differentiation into myotubes, C2C12 cells were infected 
with adenovirus encoding for GFP or PGC-1a and treated with vehicle or XCT790. Two 
days post-infection, total mitochondrial respiration and uncoupled respiration were 
measured as published 45. 
 
URLs.  The mouse genome sequence, RefSeq annotation tables, and BLASTZ 
alignments were downloaded from  http://genome.ucsc.edu.  Mappings from Affymetrix 
probe-sets to RefSeqs were performed using the NetAffx website 
(http://www.affymetrix.com).  Complete datasets used in this manuscript are available 
for download at http://www-genome.wi.mit.edu/mpg/PGC_motifs/. 
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Figure and Table Legends. 
 
Figure 1.  Schematic overview of motifADE and application to the PGC-1a 
timecourse.  (a)  motifADE attempts to identify motifs associated with differential 
expression.  It begins with a list of genes ordered on the basis of differential expression 
across two conditions (Condition 1 vs. Condition 2, e.g., healthy vs. disease tissue, 
treated vs. control, etc.).  Each gene is then annotated for the presence or absence of a 
given motif in the promoter region.  A nonparametric statistic is used to assess whether 
genes with the motif tend to rank high on this list.  In this example , genes with Motif 1 
are randomly distributed on the list, while genes with Motif 2 tend to rank high.  When 
applied to a single motif or a small set of motifs, the nominal P-value associated with the 
statistic is presented.  When we test all possible 6-9-mers, we report the Bonferroni 
corrected P-values. (b)  C2C12 cells were infected with an adenovirus expressing either 
GFP (control) or with PGC-1a and profiled over a three day period.  Experiments were 
performed in duplicate and relative gene expression measures are shown.  motifADE 
was applied to the day 3 expression levels for the 5034 genes for which reliable 
annotations of promoters are available.  Genes are ranked according to the difference in 
expression between PGC-1a and GFP on day 3.  Mouse genes having a perfect Erra 
motif (5’-TGACCTTG-3’) or Gabpa/b motif (5’-CTTCCG-3’) are labeled with a black bar 
on the right side of the correlogram.  The top 10% of all genes on this rank ordered list 
contain 25% of all genes with an Erra motif, 14% of all genes with a Gabpa motif, and 
34% of all genes containing both motifs.  Similarly, the top 25% of all genes on this rank 
ordered list contain 43% of all genes with an Erra motif, 32% of all genes with the 
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Gabpa motif, and 52% of all genes with both motifs.  (c) The expression of 525 nuclear 
encoded mitochondrial genes, based on a recent genomic and proteomic survey of 
mouse mitochondria 42, during a three day time-course following infection with PGC-1a 
or with GFP.  Genes were hierarchically clustered using dChip 41 and colors represent 
relative expression levels. 
 
Figure 2.  Proposed model of mechanism of action of PGC-1a .  PGC-1a is a highly 
regulated gene that responds to external stimuli. When PGC-1a levels rise, the 
expression of Erra and Gabpa are immediately induced via a double positive feedback 
loop.  This results in the strong induction of Erra as well as Gabpa.  These levels rise 
and over the course of 2-3 days, in which these factors couple with PGC-1a to induce 
the expression of NRF -1 as well as hundreds of effector genes. 
 
Figure 3.  Erra and Gabpa cooperate with PGC-1a to induce their own expression. 
(a) Putative Erra and Gabpa motifs 1 kb upstream and downstream of the Erra and the 
Gabpa transcriptional start sites. (b), (c), (d) C2C12 cells were transfected with a 
reporter gene plasmid containing (b) 2 kb of the Erra promoter, (c) Gabpa promoter, or 
(d) Gabpa intron 1, together with expression plasmids for Erra, Gabpa, Gabpb1 and 
PGC-1a.  48 hours post-transfection, reporter gene levels were determined and 
normalized to b-gal levels. 
 
Figure 4.  A small molecule inverse agonist of Erra  inhibits the response to PGC-
1a.  (a)  C2C12 myoblasts transfected with wildtype Erra promoter and the respective 
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expression plasmids were treated with vehicle (0.1% DMSO) or 1 mM XCT790 for 48 
hours before reporter gene levels were measured. (b)  C2C12 cells were transfected 
with wildtype or Erra-promoter harboring a mutated Erra motif (mutant) together with 
expression plasmids for Erra, Gabpa, Gabpb1 and PGC-1a.  After 48 hours, reporter 
gene levels were determined and normalized to b-gal levels. (c)  C2C12 myotubes were 
infected with GFP- or PGC-1a adenovirus and treated with vehicle (0.1% DMSO) or 1 
mM XCT790 for 1 day. Then, relative expression levels of several genes were 
determined by semiquantitative real-time PCR and normalized against 18S rRNA levels. 
(d) Fao rat hepatoma cells were infected with adenoviral GFP or PGC-1a and treated 
with vehicle (0.1% DMSO) or 1 mM XCT790 for 1 day before relative gene expression 
levels were measured by real-time PCR and normalized against 18S rRNA levels. *, 
P<0.5; ns, not significant. 
 
Figure 5.  Total and uncoupled mitochondrial respiration are inhibited by the 
synthetic Erra-inverse agonist XCT790. (a), (b) C2C12 myotubes were infected with 
GFP or PGC-1a adenovirus and treated with vehicle (0.1% DMSO) or 1 mM XCT790 for 
2 days before total mitochondrial respiration (a) and uncoupled respiration (b) was 
determined. *, P<0.5 in paired t-test. 
 
Supplemental Figure S1.  Cooperativity between the Erra and Gabpa binding sites.  
All 5034 genes from motifADE analysis are rank ordered on the basis of expression 
difference (signal:noise metric) on day 3 between cells treated with PGC-1a vs. GFP.  
The cumulative fraction of genes with a specified motif (Erra, blue;  Gabpa, pink;  both, 
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black) is plotted as a function of fractional rank ordering of all 5034 genes. Figure S2. 
Activation of PPARg does not mimic the effect of the Erra inverse agonist XCT790. 
C2C12 myotubes were infected with either GFP- or PGC-1a-encoding adenovirus and 
treated with 1 mM of rosiglitazone for 24 hours before RNA was harvested and relative 
gene expression determined using real-time PCR. Figure S3. PGC-1a-mediated 
induction of NRF-1 is decreased by the Erra inverse agonist XCT790. C2C12 myotubes 
were infected with either GFP- or PGC-1a-encoding adenovirus and treated with 1 mM 
of XCT790 for 24 hours before RNA was harvested and relative gene expression 
determined using real-time PCR. 
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Table 1.  Motifs associated with differential expression on days 1, 2, and 3.  
motifADE was performed using the mouse promoter database on each of days 1, 2, and 
3.  All motifs achieving a Bonferroni-corrected P-value < 1 x 10-3 are shown.  
Annotations of the motif and the literature references, when available, are indicated. 
       
Day Motif Frequency 
Nominal 
P-value 
Adjusted 
P-value Annotation Reference 
1 TGACCTTG 0.07 3.15E-11 2.06E-06 Erra 20 
 TGACCTTGA 0.02 4.59E-10 1.20E-04 Erra  
2 TGACCTTG 0.07 4.44E-14 2.91E-09 Erra 20 
 TGACCTT 0.16 3.62E-12 5.93E-08 Erra  
 TGACCT 0.45 1.46E-11 5.97E-08 NR half-site 46 
 GACCTTG 0.16 7.92E-11 1.30E-06 Erra  
 GACCTT 0.41 1.42E-09 5.81E-06 Erra  
  TTGACC 0.27 2.42E-07 9.92E-04 Erra  
3 CTTCCG 0.33 2.19E-12 8.97E-09 Gabpa 47 
 TGACCTTG 0.07 1.17E-11 7.66E-07 Erra 20 
 TGACCTT 0.16 1.23E-10 2.02E-06 Erra  
 CCCGCC 0.54 2.04E-08 8.36E-05   
 GCGGCG 0.43 3.78E-08 1.55E-04   
 AGGTCA 0.42 3.90E-08 1.60E-04 NR half-site 46 
 CTTCCGG 0.16 1.95E-08 3.19E-04 Gabpa  
 TTCCGG 0.31 1.09E-07 4.46E-04 Gabpa  
 GGGGCG 0.54 1.24E-07 5.08E-04   
 TTCCGCT 0.07 3.30E-08 5.41E-04 Gabpa  
 GCCGGC 0.42 1.57E-07 6.44E-04   
  ACTTCCG 0.09 5.11E-08 8.38E-04 Gabpa  
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Supplemental Table S1.  Motifs discovered using the promoter database 
achieving P<0.05.  motifADE was performed using the mouse promoter database on 
each of days 1, 2, and 3.  Motifs achieving a Bonferroni-corrected P-value < 0.05 are 
shown. 
 
Day Motif Frequency P-value  Adjusted P-value 
1 TGACCTTG  0.07 3.15E-11 2.06E-06 
 TGACCTTGA 0.02 4.59E-10 1.20E-04 
 GACCTTGA 0.05 5.76E-08 3.77E-03 
 GACCTTG 0.16 1.54E-06 2.53E-02 
  GTCACG 0.18 8.04E-06 3.29E-02 
2 TGACCTTG  0.07 4.44E-14 2.91E-09 
 TGACCTT 0.16 3.62E-12 5.93E-08 
 TGACCT 0.45 1.46E-11 5.97E-08 
 GACCTTG 0.16 7.92E-11 1.30E-06 
 GACCTT 0.41 1.42E-09 5.81E-06 
 TTGACC 0.27 2.42E-07 9.92E-04 
 GTGACCTT 0.05 3.86E-08 2.53E-03 
 GTGACCT 0.15 3.91E-07 6.41E-03 
 GTGACCTTG 0.02 3.97E-08 1.04E-02 
 TGACCTTGA 0.02 4.63E-08 1.21E-02 
 AGGTCA 0.42 3.46E-06 1.42E-02 
 CGCTGAGG 0.04 3.06E-07 2.01E-02 
 GACCTTGA 0.05 3.33E-07 2.19E-02 
 AGGTCAC 0.13 1.99E-06 3.26E-02 
  GTGACC 0.40 8.80E-06 3.61E-02 
3 CTTCCG 0.33 2.19E-12 8.97E-09 
 TGACCTTG  0.07 1.17E-11 7.66E-07 
 TGACCTT 0.16 1.23E-10 2.02E-06 
 CCCGCC 0.54 2.04E-08 8.36E-05 
 GCGGCG 0.43 3.78E-08 1.55E-04 
 AGGTCA 0.42 3.90E-08 1.60E-04 
 CTTCCGG 0.16 1.95E-08 3.19E-04 
 TTCCGG 0.31 1.09E-07 4.46E-04 
 GGGGCG 0.54 1.24E-07 5.08E-04 
 TTCCGCT 0.07 3.30E-08 5.41E-04 
 GCCGGC 0.42 1.57E-07 6.44E-04 
 ACTTCCG 0.09 5.11E-08 8.38E-04 
 GACCTT 0.41 2.72E-07 1.11E-03 
 CGGGGC 0.51 4.86E-07 1.99E-03 
 ATGGCGGC 0.05 4.76E-08 3.12E-03 
 GACCTTG 0.16 1.90E-07 3.12E-03 
 CTTCCGGC 0.05 7.34E-08 4.81E-03 
 ATGGCGG 0.11 3.24E-07 5.31E-03 
 AAGATGGCG 0.03 2.07E-08 5.43E-03 
 CCGGGG 0.47 1.43E-06 5.85E-03 
 GCGGAC 0.24 1.52E-06 6.23E-03 
 GGCGGC 0.48 1.55E-06 6.35E-03 
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 TCACGG 0.19 1.79E-06 7.31E-03 
 GTGACCTT 0.05 1.23E-07 8.07E-03 
 CCGGCT 0.39 2.23E-06 9.13E-03 
 GGCCGG 0.47 2.24E-06 9.16E-03 
 TCACCG 0.21 2.79E-06 1.14E-02 
 GCCGGG 0.49 2.81E-06 1.15E-02 
 CGCCTT 0.30 2.93E-06 1.20E-02 
 CGGACC 0.24 3.33E-06 1.36E-02 
 TTCCGC 0.23 3.42E-06 1.40E-02 
 CGCTGA 0.26 3.44E-06 1.41E-02 
 CCCCGC 0.51 3.55E-06 1.46E-02 
 CGCGAG 0.24 3.71E-06 1.52E-02 
 GTCACG 0.18 4.14E-06 1.69E-02 
 CGTCCT 0.25 4.15E-06 1.70E-02 
 AAGGTCA 0.15 1.28E-06 2.10E-02 
 GCCCGG 0.49 5.14E-06 2.11E-02 
 CCGCCG 0.36 5.25E-06 2.15E-02 
 TCCGGG 0.42 5.75E-06 2.35E-02 
 AAGATGGC 0.08 3.93E-07 2.57E-02 
 GGCGGA 0.40 6.56E-06 2.69E-02 
 GGGCGG 0.58 7.63E-06 3.12E-02 
 CGGGCG 0.38 7.77E-06 3.18E-02 
 ACCCCG 0.31 8.07E-06 3.30E-02 
 CGCGCC 0.37 8.13E-06 3.33E-02 
 CGCCTC 0.41 9.12E-06 3.74E-02 
 TTCCCG 0.34 9.44E-06 3.86E-02 
 GGGTCGTGG 0.01 1.56E-07 4.09E-02 
 CGGCGG 0.40 1.01E-05 4.15E-02 
 CCGGAA 0.30 1.14E-05 4.68E-02 
  CGTCGC 0.16 1.15E-05 4.73E-02 
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Supplemental Table S2.  Motifs discovered using the masked promoter database achieving 
P<0.05.  motifADE was performed using the ‘masked promoter database’, consisting of regions 
of the promoters aligned and conserved between mouse and human.  Motifs achieving a 
Bonferroni-corrected P-value < 0.05 are shown.   
 
Day Motif Frequency P-value Adjusted P-value 
1 TGACCTTG  0.04 9.93E-12 6.51E-07 
 TGACCTT 0.09 2.10E-09 3.44E-05 
 GACCTTGA 0.02 4.91E-08 3.22E-03 
 GTGACCTTG 0.02 4.30E-08 1.13E-02 
  TGACCTTGA 0.01 4.92E-08 1.29E-02 
2 TGACCTT 0.09 1.09E-14 1.78E-10 
 TGACCT 0.26 4.56E-13 1.87E-09 
 GTGACCTT 0.03 6.37E-13 4.18E-08 
 TGACCTTG  0.04 8.30E-11 5.44E-06 
 GTGACCT 0.09 5.72E-10 9.37E-06 
 AGGTCA 0.25 2.90E-09 1.19E-05 
 GACCTT 0.24 8.67E-09 3.55E-05 
 GACCTTG 0.09 4.78E-08 7.84E-04 
 ACCTTG 0.22 1.06E-06 4.33E-03 
 TGTGACCTT 0.01 6.13E-08 1.61E-02 
 GTGACCTTG 0.02 1.14E-07 2.98E-02 
 AGGTCAC 0.08 2.01E-06 3.29E-02 
  ACCTTGA 0.06 2.63E-06 4.30E-02 
3 TGACCTT 0.09 4.40E-14 7.20E-10 
 TGACCTTG  0.04 6.24E-12 4.09E-07 
 GTGACCTT 0.03 1.37E-11 8.97E-07 
 GTGACCT 0.09 7.06E-11 1.16E-06 
 CTTCCG 0.26 1.28E-08 5.26E-05 
 TGACCT 0.26 2.11E-08 8.64E-05 
 ATGGCGGC 0.05 2.87E-09 1.88E-04 
 GACCTT 0.24 8.73E-08 3.57E-04 
 AGGTCA 0.25 9.47E-08 3.88E-04 
 AAGATGGCG 0.03 1.70E-09 4.45E-04 
 CGGTGA 0.20 1.81E-07 7.41E-04 
 AGATGGCG 0.04 1.31E-08 8.61E-04 
 CTTCCGG 0.12 1.66E-07 2.72E-03 
 GACCTTG 0.09 2.66E-07 4.35E-03 
 AGATGGCGG 0.02 2.22E-08 5.81E-03 
 ATGGCGG 0.10 4.34E-07 7.11E-03 
 CCGGGG 0.39 1.80E-06 7.39E-03 
 GGCGGG 0.53 2.33E-06 9.56E-03 
 ACTTCCG 0.08 1.19E-06 1.94E-02 
 CGGAAGT 0.08 1.24E-06 2.04E-02 
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 CTTCCGGC 0.04 3.20E-07 2.10E-02 
 TGGCGGC 0.16 1.70E-06 2.78E-02 
 CCGGCT 0.28 9.09E-06 3.72E-02 
 TGACCTTGA 0.01 1.50E-07 3.93E-02 
 AAGATGGCGG 0.02 4.08E-08 4.28E-02 
 GAGGTCA 0.08 2.68E-06 4.40E-02 
  GCGGAA 0.18 1.15E-05 4.73E-02 
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